Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2001 Apr;77(906):230–234. doi: 10.1136/pmj.77.906.230

The immunocompromised patient and transfusion

K Badami 1
PMCID: PMC1741972  PMID: 11264483

Full Text

The Full Text of this article is available as a PDF (134.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abstracts of papers selected for presentation at the joint meeting of the British Society for Haematology and the British Blood Transfusion Society. London, 10 November 1989. Br J Haematol. 1989 Dec;73(4):584–585. doi: 10.1111/j.1365-2141.1989.tb00313.x. [DOI] [PubMed] [Google Scholar]
  2. Anderson K. C., Weinstein H. J. Transfusion-associated graft-versus-host disease. N Engl J Med. 1990 Aug 2;323(5):315–321. doi: 10.1056/NEJM199008023230506. [DOI] [PubMed] [Google Scholar]
  3. Bordin J. O., Bardossy L., Blajchman M. A. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. Blood. 1994 Jul 1;84(1):344–348. [PubMed] [Google Scholar]
  4. Bordin J. O., Heddle N. M., Blajchman M. A. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994 Sep 15;84(6):1703–1721. [PubMed] [Google Scholar]
  5. Brubaker D. B. Human posttransfusion graft-versus-host disease. Vox Sang. 1983;45(6):401–420. doi: 10.1111/j.1423-0410.1983.tb01937.x. [DOI] [PubMed] [Google Scholar]
  6. Bruil A., Beugeling T., Feijen J., van Aken W. G. The mechanisms of leukocyte removal by filtration. Transfus Med Rev. 1995 Apr;9(2):145–166. doi: 10.1016/s0887-7963(05)80053-7. [DOI] [PubMed] [Google Scholar]
  7. Burns L. J., Westberg M. W., Burns C. P., Klassen L. W., Goeken N. E., Ray T. L., Macfarlane D. E. Acute graft-versus-host disease resulting from normal donor blood transfusions. Acta Haematol. 1984;71(4):270–276. doi: 10.1159/000206599. [DOI] [PubMed] [Google Scholar]
  8. Button L. N., DeWolf W. C., Newburger P. E., Jacobson M. S., Kevy S. V. The effects of irradiation on blood components. Transfusion. 1981 Jul-Aug;21(4):419–426. doi: 10.1046/j.1537-2995.1981.21481275998.x. [DOI] [PubMed] [Google Scholar]
  9. Capon S. M., Sacher R. A., Deeg H. J. Effective ultraviolet irradiation of platelet concentrates in teflon bags. Transfusion. 1990 Oct;30(8):678–681. doi: 10.1046/j.1537-2995.1990.30891020323.x. [DOI] [PubMed] [Google Scholar]
  10. Chung M., Steinmetz O. K., Gordon P. H. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg. 1993 Apr;80(4):427–432. doi: 10.1002/bjs.1800800407. [DOI] [PubMed] [Google Scholar]
  11. Dinsmore R. E., Straus D. J., Pollack M. S., Woodruff J. M., Garrett T. J., Young C. W., Clarkson B. D., Dupont B. Fatal graft-versus-host disease following blood transfusion in Hodgkin's disease documented by HLA typing. Blood. 1980 May;55(5):831–834. [PubMed] [Google Scholar]
  12. Dzieczkowski J. S., Barrett B. B., Nester D., Campbell M., Cook J., Sugrue M., Andersen J. W., Anderson K. C. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion. 1995 Jan;35(1):20–25. doi: 10.1046/j.1537-2995.1995.35195090654.x. [DOI] [PubMed] [Google Scholar]
  13. Ford J. M., Cullen M. H., Lucey J. J., Tobias J. S., Lister T. A. Fatal graft-versus-host disease following transfusion of granulocytes from normal donors. Lancet. 1976 Nov 27;2(7996):1167–1169. doi: 10.1016/s0140-6736(76)91682-2. [DOI] [PubMed] [Google Scholar]
  14. Frickhofen N., Abkowitz J. L., Safford M., Berry J. M., Antunez-de-Mayolo J., Astrow A., Cohen R., Halperin I., King L., Mintzer D. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990 Dec 15;113(12):926–933. doi: 10.7326/0003-4819-113-12-926. [DOI] [PubMed] [Google Scholar]
  15. Fried M. R., Eastlund T., Christie B., Mullin G. T., Key N. S. Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy. Transfusion. 1996 Oct;36(10):900–903. doi: 10.1046/j.1537-2995.1996.361097017177.x. [DOI] [PubMed] [Google Scholar]
  16. Goldman M., Delage G. The role of leukodepletion in the control of transfusion-transmitted disease. Transfus Med Rev. 1995 Jan;9(1):9–19. doi: 10.1016/s0887-7963(05)80027-6. [DOI] [PubMed] [Google Scholar]
  17. Grundy J. E., Shanley J. D., Griffiths P. D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet. 1987 Oct 31;2(8566):996–999. doi: 10.1016/s0140-6736(87)92560-8. [DOI] [PubMed] [Google Scholar]
  18. Hanto D. W., Gajl-Peczalska K. J., Frizzera G., Arthur D. C., Balfour H. H., Jr, McClain K., Simmons R. L., Najarian J. S. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg. 1983 Sep;198(3):356–369. doi: 10.1097/00000658-198309000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Heddle N. M., Klama L., Singer J., Richards C., Fedak P., Walker I., Kelton J. G. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med. 1994 Sep 8;331(10):625–628. doi: 10.1056/NEJM199409083311001. [DOI] [PubMed] [Google Scholar]
  20. Hillyer C. D., Emmens R. K., Zago-Novaretti M., Berkman E. M. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units. Transfusion. 1994 Oct;34(10):929–934. doi: 10.1046/j.1537-2995.1994.341095026982.x. [DOI] [PubMed] [Google Scholar]
  21. Hillyer C. D., Snydman D. R., Berkman E. M. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: transfusion of blood products. Transfusion. 1990 Sep;30(7):659–666. doi: 10.1046/j.1537-2995.1990.30790385528.x. [DOI] [PubMed] [Google Scholar]
  22. James D. J., Sikotra S., Sivakumaran M., Wood J. K., Revill J. A., Bullen V., Myint S. The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets. Transfus Med. 1997 Jun;7(2):123–126. doi: 10.1046/j.1365-3148.1997.d01-14.x. [DOI] [PubMed] [Google Scholar]
  23. Juji T., Takahashi K., Shibata Y., Ide H., Sakakibara T., Ino T., Mori S. Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med. 1989 Jul 6;321(1):56–56. doi: 10.1056/NEJM198907063210116. [DOI] [PubMed] [Google Scholar]
  24. Kurtzman G. J., Cohen B., Meyers P., Amunullah A., Young N. S. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet. 1988 Nov 19;2(8621):1159–1162. doi: 10.1016/s0140-6736(88)90233-4. [DOI] [PubMed] [Google Scholar]
  25. Kurtzman G. J., Ozawa K., Cohen B., Hanson G., Oseas R., Young N. S. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med. 1987 Jul 30;317(5):287–294. doi: 10.1056/NEJM198707303170506. [DOI] [PubMed] [Google Scholar]
  26. Linden J. V., Pisciotto P. T. Transfusion-associated graft-versus-host disease and blood irradiation. Transfus Med Rev. 1992 Apr;6(2):116–123. doi: 10.1016/s0887-7963(92)70161-8. [DOI] [PubMed] [Google Scholar]
  27. Luban N. L. Human parvoviruses: implications for transfusion medicine. Transfusion. 1994 Sep;34(9):821–827. doi: 10.1046/j.1537-2995.1994.34994378286.x. [DOI] [PubMed] [Google Scholar]
  28. Miller W. J., McCullough J., Balfour H. H., Jr, Haake R. J., Ramsay N. K., Goldman A., Bowman R., Kersey J. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 1991 Mar;7(3):227–234. [PubMed] [Google Scholar]
  29. Nagai K., Morohoshi T., Kudoh T., Yoto Y., Suzuki N., Matsunaga Y. Transient erythroblastopenia of childhood with megakaryocytopenia associated with human parvovirus B19 infection. Br J Haematol. 1992 Jan;80(1):131–132. doi: 10.1111/j.1365-2141.1992.tb06416.x. [DOI] [PubMed] [Google Scholar]
  30. Ohto H., Anderson K. C. Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion. 1996 Feb;36(2):117–123. doi: 10.1046/j.1537-2995.1996.36296181922.x. [DOI] [PubMed] [Google Scholar]
  31. Oksanen K., Elonen E. Impact of leucocyte-depleted blood components on the haematological recovery and prognosis of patients with acute myeloid leukaemia. Finnish Leukemia Group. Br J Haematol. 1993 Aug;84(4):639–647. doi: 10.1111/j.1365-2141.1993.tb03140.x. [DOI] [PubMed] [Google Scholar]
  32. Petz L. D., Calhoun L., Yam P., Cecka M., Schiller G., Faitlowicz A. R., Herron R., Sayah D., Wallace R. B., Belldegrun A. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion. 1993 Sep;33(9):742–750. doi: 10.1046/j.1537-2995.1993.33994025025.x. [DOI] [PubMed] [Google Scholar]
  33. Popovsky M. A. Quality of blood components filtered before storage and at the beside: implications for transfusion practice. Transfusion. 1996 May;36(5):470–474. doi: 10.1046/j.1537-2995.1996.36596282594.x. [DOI] [PubMed] [Google Scholar]
  34. Preiksaitis J. K. Indications for the use of cytomegalovirus-seronegative blood products. Transfus Med Rev. 1991 Jan;5(1):1–17. doi: 10.1016/s0887-7963(91)70189-2. [DOI] [PubMed] [Google Scholar]
  35. Saarinen U. M., Koskimies S., Myllylä G. Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer. Vox Sang. 1993;65(4):286–292. doi: 10.1111/j.1423-0410.1993.tb02168.x. [DOI] [PubMed] [Google Scholar]
  36. Sanders M. R., Graeber J. E. Posttransfusion graft-versus-host disease in infancy. J Pediatr. 1990 Jul;117(1 Pt 1):159–163. doi: 10.1016/s0022-3476(05)82460-6. [DOI] [PubMed] [Google Scholar]
  37. Sayers M. H., Anderson K. C., Goodnough L. T., Kurtz S. R., Lane T. A., Pisciotto P., Silberstein L. E. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med. 1992 Jan 1;116(1):55–62. doi: 10.7326/0003-4819-116-1-55. [DOI] [PubMed] [Google Scholar]
  38. Sazama K. Bacteria in blood for transfusion. A review. Arch Pathol Lab Med. 1994 Apr;118(4):350–365. [PubMed] [Google Scholar]
  39. Shanwell A., Kristiansson M., Remberger M., Ringdén O. Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion. 1997 Jul;37(7):678–684. doi: 10.1046/j.1537-2995.1997.37797369441.x. [DOI] [PubMed] [Google Scholar]
  40. Sprent J., Anderson R. E., Miller J. F. Radiosensitivity of T and B lymphocytes. II. Effect of irradiation on response of T cells to alloantigens. Eur J Immunol. 1974 Mar;4(3):204–210. doi: 10.1002/eji.1830040310. [DOI] [PubMed] [Google Scholar]
  41. Strobel S., Morgan G., Simmonds A. H., Levinsky R. J. Fatal graft versus host disease after platelet transfusions in a child with purine nucleoside phosphorylase deficiency. Eur J Pediatr. 1989 Jan;148(4):312–314. doi: 10.1007/BF00444121. [DOI] [PubMed] [Google Scholar]
  42. Thaler M., Shamiss A., Orgad S., Huszar M., Nussinovitch N., Meisel S., Gazit E., Lavee J., Smolinsky A. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med. 1989 Jul 6;321(1):25–28. doi: 10.1056/NEJM198907063210105. [DOI] [PubMed] [Google Scholar]
  43. Transfusion-transmitted CMV infections. Clinical importance and means of prevention? Vox Sang. 1984;46(6):387–414. doi: 10.1111/j.1423-0410.1984.tb00103.x. [DOI] [PubMed] [Google Scholar]
  44. Triulzi D. J., Vanek K., Ryan D. H., Blumberg N. A clinical and immunologic study of blood transfusion and postoperative bacterial infection in spinal surgery. Transfusion. 1992 Jul-Aug;32(6):517–524. doi: 10.1046/j.1537-2995.1992.32692367194.x. [DOI] [PubMed] [Google Scholar]
  45. Vamvakas E. C. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion. 1996 Feb;36(2):175–186. doi: 10.1046/j.1537-2995.1996.36296181932.x. [DOI] [PubMed] [Google Scholar]
  46. Van Buren N. L., Stroncek D. F., Clay M. E., McCullough J., Dalmasso A. P. Transfusion-related acute lung injury caused by an NB2 granulocyte-specific antibody in a patient with thrombotic thrombocytopenic purpura. Transfusion. 1990 Jan;30(1):42–45. doi: 10.1046/j.1537-2995.1990.30190117629.x. [DOI] [PubMed] [Google Scholar]
  47. Wagner S. J., Friedman L. I., Dodd R. Y. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. Transfus Med Rev. 1991 Jan;5(1):18–32. doi: 10.1016/s0887-7963(91)70190-9. [DOI] [PubMed] [Google Scholar]
  48. Williams M. D., Cohen B. J., Beddall A. C., Pasi K. J., Mortimer P. P., Hill F. G. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang. 1990;58(3):177–181. doi: 10.1111/j.1423-0410.1990.tb02086.x. [DOI] [PubMed] [Google Scholar]
  49. von Fliedner V., Higby D. J., Kim U. Graft-versus-host reaction following blood product transfusion. Am J Med. 1982 Jun;72(6):951–961. doi: 10.1016/0002-9343(82)90857-9. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES